Windtree Therapeutics Faces Delisting Concerns
Ticker: WINTW · Form: 8-K · Filed: Aug 20, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Aug 20, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, listing-standards
TL;DR
Windtree Therapeutics might get delisted - stock exchange rules are a problem.
AI Summary
Windtree Therapeutics, Inc. filed an 8-K on August 20, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, formerly known as Discovery Laboratories Inc., is incorporated in Delaware and has its principal business address in Warrington, Pennsylvania.
Why It Matters
This filing indicates potential issues with Windtree Therapeutics' compliance with stock exchange listing requirements, which could impact its stock's tradability and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation as a publicly traded entity.
Key Numbers
- 001-39290 — Commission File Number (Identifies the company's SEC filings)
- 94-3171943 — I.R.S. Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- Discovery Laboratories Inc. (company) — Former company name
- August 19, 2025 (date) — Earliest event reported date
- August 20, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Warrington, Pennsylvania (location) — Principal business address
FAQ
What specific listing rule or standard has Windtree Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Windtree Therapeutics has failed to satisfy, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is August 19, 2025.
What is Windtree Therapeutics' former company name?
Windtree Therapeutics, Inc. was formerly known as Discovery Laboratories Inc.
In which state is Windtree Therapeutics incorporated?
Windtree Therapeutics, Inc. is incorporated in Delaware.
What is the principal business address of Windtree Therapeutics?
The principal business address is 2600 Kelly Road, Suite 100, Warrington, Pennsylvania 18976.
Filing Stats: 895 words · 4 min read · ~3 pages · Grade level 13.7 · Accepted 2025-08-20 12:15:15
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share WINT The Nasdaq Capital M
Filing Documents
- wint20250820_8k.htm (8-K) — 25KB
- 0001437749-25-027421.txt ( ) — 153KB
- wint-20250819.xsd (EX-101.SCH) — 3KB
- wint-20250819_def.xml (EX-101.DEF) — 11KB
- wint-20250819_lab.xml (EX-101.LAB) — 15KB
- wint-20250819_pre.xml (EX-101.PRE) — 11KB
- wint20250820_8k_htm.xml (XML) — 3KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 19, 2025, Windtree Therapeutics Inc. (the " Company " ) was notified by The Nasdaq Stock Market LLC (" Nasdaq ") that as a result of the Company's previously disclosed noncompliance with Nasdaq Listing Rule 5550(a)(2), Nasdaq has determined to delist the Company's common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company's common stock effective at the open of trading on August 21, 2025. The Company expects that its common stock will begin trading publicly on the over-the-counter market on August 21, 2025, under its existing symbol "WINT." The Company has applied to be traded on the OTCID tier of the OTC Market. However, there can be no assurance that the Company will be approved for trading on the OTCID. The transition to the quotation of the Company's common stock on the OTC Markets will have no effect on the Company's business or operations. The Company will continue to file periodic and other required reports with the Securities and Exchange Commission (the " SEC ") under applicable federal securities laws, which will be available on the SEC's website, www.SEC.gov . Cautionary Statement Regarding Forward-Looking Statements This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, the Company's expectation that it will commence trading its common stock on the OTCID tier. In some cases, you can identify forward-looking statements by terminology such as "outlook," "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "ex
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Windtree Therapeutics, Inc. By: /s/ Jed Latkin Name: Jed Latkin Title: President and Chief Executive Officer Date: August 20, 2025